CCT6A and neoplasm: Di Meo et al. (2019) reported that CCT6A was a potential prognostic biomarker in renal cell carcinoma. Klimczak et al. (2019) also suggested that CCT6A may be involved in imparting an unfavorable prognosis in breast cancer tumor progression. Despite this, the involvement of CCT6A in COAD has not been clarified.